- Nestoron
-
- $35.00
-
2026-07-27
- CAS:7759-35-5
- Purity: 99.92%
- Supply Ability: 10g
- Nestoron
-
-
2026-07-26
- CAS:7759-35-5
- Min. Order: 100GRAM
- Purity: 99%
- Supply Ability: 500KGS
- Nestoron
-
- $1.00
-
2019-07-06
- CAS:7759-35-5
- Min. Order: 1G
- Purity: 98%
- Supply Ability: 100KG
|
| | Nestoron Basic information |
| Product Name: | Nestoron | | Synonyms: | ST 1435;NESTORON;17-Hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione acetate;Elcometrine;17-(ACETYLOXY)-16-METHYLENE-19-NORPREGN-4-ENE-20-DIONE;16-Methylene-17-hydroxy-19-norpregn-4-ene-3,20-dione acetate;16-Methylene-17-alpha-acetoxy-19-nor-4-pregnene-3,20-dione;19-Norpregn-4-ene-3,20-dione, 17-(acetyloxy)-16-methylene- (9ci) | | CAS: | 7759-35-5 | | MF: | C23H30O4 | | MW: | 370.48 | | EINECS: | | | Product Categories: | API | | Mol File: | 7759-35-5.mol |  |
| | Nestoron Chemical Properties |
| Melting point | 178-179° | | alpha | D21 -105° (c = 1.2 in chloroform) | | Boiling point | 420.37°C (rough estimate) | | density | 1.0550 (rough estimate) | | refractive index | 1.4433 (estimate) | | storage temp. | 2-8°C | | solubility | DMSO: soluble5mg/mL, clear | | form | powder | | color | white to beige | | InChI | InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1 | | InChIKey | CKFBRGLGTWAVLG-GOMYTPFNSA-N | | SMILES | C1(=O)C=C2[C@]([H])(CC1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)[C@@](OC(C)=O)(C(=O)C)C(=C)C3)CC2 |
| | Nestoron Usage And Synthesis |
| Uses | Segesterone Acetate has been used to study the: comparison of androgenic and estrogenic properties of progestins used in contraception and hormone therapy; impact on hepatic estrogen-sensitive proteins by 1-yr contraceptive vaginal ring delivering Nestorone and ethinyl estradiol. | | Definition | ChEBI: Elcometrine is a corticosteroid hormone. | | Pharmacokinetics | Elcometrine is a member of the 19-norprogesterone class of pr ogestins. when administered subcuta neously (implant), intravaginally (vaginal ring), or transdermally, elcometrine is an exceptionally potent progestin. It is 100-fold more potent when administered subcutaneously than when delivered orally. Its oral bioavaiability is only 10%，with a half life of just 1 to 2 hours because of rapid metabolism. The C16 methylene functionality substantially increases its affinity for the progesterone receptor. | | Clinical Use | Because of its antiestrogenic action, elcometrine also can be administered transdermally along with estradiol as a treatment for menopausal symptoms . | | in vivo | Nestoron (400 μCi 3H Nestoron/kg BW; subcutaneous injection; female Sprague-Dawley rats) treatment results in the Cmax in the blood and plasma are 58.1 and 95.5 ng equiv. 3H Nestoron/g, with t1/2 of 15.6 hours. Approximately, 81.4% and 7.62% of the administered dose is excreted via feces and urine, respectively[1]. | Animal Model: | 27 adult, female, Sprague-Dawley rats (200-225 g; age: 8 weeks)[1] | | Dosage: | 400 μCi 3H Nestorone/kg BW | | Administration: | Subcutaneous injection (Pharmacokinetic study) | | Result: | The mean peak concentrations of radioactivity (Cmax) in the blood and plasma were 58.1 and 95.5 ng equiv./g, with t1/2 of 15.6 hours. Approximately, 81.4% and 7.62% of the administered dose was excreted via feces and urine, respectively.
|
|
| | Nestoron Preparation Products And Raw materials |
|